22 23 Keywords: Alzheimer's disease, cortical grey matter, extracellular vesicles, microtubule-24 associated protein tau, amyloid beta peptide, proteome, machine learning 25 26 Abstract 27 Introduction: Extracellular vesicles (EVs) from human Alzheimer's disease (AD) biospecimens 28 contain amyloid-β peptide (Aβ) and tau. While AD EVs are known to affect brain disease 29 pathobiology, their biochemical and molecular characterizations remain ill defined. 30 Methods: EVs were isolated from the cortical grey matter of 20 AD and 18 control brains. Tau 31 and Aβ levels were measured by immunoassay. Differentially expressed EV proteins were 32 assessed by quantitative proteomics and machine learning. 33 Results: Levels of pS396 tau and Aβ were significantly elevated in AD EVs. High levels of 34 neuron-and glia-specific factors are detected in control and AD EVs, respectively. Machine 35 learning identified ANXA5, VGF, GPM6A and ACTZ in AD EV compared to controls. They 36 distinguished AD EVs from controls in the test sets with 88% accuracy. 37 Discussion: In addition to Aβ and tau, ANXA5, VGF, GPM6A and ACTZ are new signature 38 proteins in AD EVs. 39 40 1. Background 41
enzymatic degradation of Aβ and promote both Aβ aggregation and clearance by microglia 64 [16, 17] . Moreover, models of neuron-to-neuron transfer of tau seeds by EVs were reported 65 [12, [18] [19] [20] . Our own prior work demonstrated that microglia spread tau by EV secretion and that 66 reducing EV synthesis significantly reduces tau propagation [10] . One mechanism centers 67 around Bridging integrator 1 (BIN1), which is associated with the progression of tau pathology 68 and observed by its abilities to alter tau clearance and by promoting the release of tau-enriched 69 microglial EVs [21] . 70 While EVs recovered from human and mouse brain tissues were examined by 71 morphology, proteomics and RNA analyses [22] [23] [24] [25] , no comprehensive and quantitative 72 proteomics database have yet been acquired for AD human brain tissues. Herein, we provide the 73 first proteomic profiling of EVs isolated from postmortem AD and cognitively impaired control 74 brain tissues . The analyses were combined with machine learning and quantitation of Aβ and tau 75 species by epitope-specific ELISA. Machine learning identified and distinguished protein 76 signatures of AD brain-derived EVs from controls with high degrees of accuracy. 77 78 2. Methods 79
Brain sample acquisitions 80
Two cohorts of brains were used in this study. The first cohort was obtained from the University 81 of Nebraska Medical School (11 AD and 9 control) and the Greater Los Angeles Veteran's 82 Affairs Hospital (9 AD and 9 control) as part of NIH NeuroBioBank, which were matched for 83 age and sex. The second cohort was obtained from the NIH NeuroBioBank (22 AD and 18 84 control ), All were matched for age and sex. The Institutional Review Board at the University of NeuroBioBank approved the brain acquisitions provided by informed consent. 87 2.2. Purification of EVs from human brain samples 88 0.5 g of largely grey matter tissue from the frontal cortex of deceased AD or control cases were 89 processed for EV extraction based on reported method with some modifications [23] . Briefly, 90 frozen brain tissue was chopped on ice using a razor blade (# 12-640 Fischer Scientific) to 91 generate 2-3mm 3 sections. The sections were transferred to 3mL of Hibernate E solution 92 containing 20 units of Papain (# LK003178 Worthington-biochemical corporation) in Earle's 93
Balanced Salt Solution (EBSS) (# 14155063 Gibco) and then incubated in a water bath at 37°C 94 for 15 minutes by stirring once every 5 minutes. After incubation, the samples were immediately 95 place on ice, and 6mL of ice-cold Hibernate E solution (# A1247601 Gibco). The dissociated 96 brain tissue samples were gently homogenized (20 strokes) with a glass-Teflon homogenizer (# 97 89026-384 VWR). The homogenized tissue samples were filtered with 40 μ m mesh filter (# 22-98 double-filtered PBS (dfPBS) with 0.22-μm pore size (# SLGP033RS EMD Millipore). The sucrose step gradient was created with six 2-mL steps starting from 2.0 M to 1.5M, 1.0M, 110 0.825M, 0.65M, and 0.475M (containing the resuspended pellet) in a polyallomer ultracentrifuge 111 tube. Each layer was colored with commercially available food coloring to facilitate capture of 112 the EV-rich interphase present between certain steps. The gradient was centrifuged at 200,000 × 113 g for 20 h at 4°C (35,000 rpm with # Optima-XE SW41 Beckman Coulter), after centrifugation, 114 the gradient was collected in 2mL fractions, except for the first and last fractions, which were 115 1mL each. Fraction III corresponded to the 1mL removed from the tube, and particles in this area 116 had a buoyant density of approximately 1.08 g/cm 3 . The area between the second (0.65M) and 117 third (0.825M) steps was collected and corresponded to fraction "V", with a buoyant density of 118 1.10 -1.12 g/cm 3 , while the interphase between the third and fourth steps corresponded to 119 fraction "VI", with a buoyant density of 1.12 -1.15 g/cm 3 . The V and VI fractions were then 120 diluted separately to a total volume of 12mL with dfPBS and centrifuged at 100,000 × g for 70 121 min at 4°C (# Optima-XE SW41 Beckman Coulter). The final pellet from each fraction was 122 resuspended in 30 μ L of dfPBS. For all biochemical analyses, these fractions were combined 123 such that an equal volume of each fraction (V and VI) was used. For proteomics, an equal 124 amount of total protein from each fraction (V and VI) was used. 125
Particle counts were normalized for dilution on the machine, dilution of the final pellet, and starting material for EVs extraction. The average count was then taken for fractions V and VI. 156
Transmission electron microscopy (TEM) 157
The EV isolated from AD or control brain tissue were analyzed by TEM. 5µl of the EV sample 158 was adsorbed for 1 min to a carbon-coated mesh grid (# CF400-CU EMS www.emsdiasum.com) 159 that had been made hydrophilic by a 20-sec exposure to a glow discharge (25mA). Excess liquid 160 was removed with a filter paper (# 1 Whatman), the grid was then floated briefly on a drop of 161 water (to wash away phosphate or salt), blotted on a filer paper, and then stained with 0.75% 162 uranyl formate (# 22451 EMS) for 30 sec. After removing the excess uranyl formate with a filter 163 paper, the grids were examined and random fields were photographed using a JEOL 1200EX 164 TEM with an AMT 2k CCD camera. (Table 1 ). There were 236 no statistical differences in the demographics between AD and controls with the exception of 237 postmoterm intervals (PMI) of the validation set, which will be discussed in the validation study 238 ( Figure 4E) . 239 240
Experimental workflow 241
The experimental workflow is summarized in Figure 1A . The EVs were isolated from 20 AD 242 and 18 sex-and age-matched cognitively unimpaired controls using the discontinuous sucrose 243 gradient ultracentrifugation as previously described with modifications (see Materials and
Biochemical characterization of brain-derived EVs 247
To determine the purity of the EV preparations, NTA was deployed to determine the size of 248 suspended particles based on their Brownian motion. Two cohorts of brain EVs (AD and control) 249 and analyzed their size and number by NTA. The concentration of EVs derived from AD and 250 control brains were not significantly different (p = 0.6075). The mode size distribution for EVs 251 was significantly different and peaked at 122 nm for AD and 131 nm for controls (p = 0.0095) 252
( Figure 1B) . The EVs isolated from frozen brain tissue showed cap-shaped morphology by 253 transmission electron microscopy (TEM) ( Figure 1C) . To characterize the AD-related proteins 254 in brain-derived EVs, we measured the concentration of total tau (t-tau) and p-tau at threonine 255 181 (pT181 tau), serine 199 (pS199 tau) and serine 396 (pS396 tau) in lysed EVs by ELISA. The 256 levels of t-tau, pT181 tau, and pS199 tau showed no significant differences between AD and 257 controls (t-tau: p = 0.398, pT181 tau: p = 0.7235, and pS199 tau: p = 0.4384) ( Figure 1D) . 258
Conversely, pS396 tau was significantly increased in AD-brain derived EVs over controls 259 (pS396 tau: p = 0.0375) ( Figure 1D) . Moreover, we observed a significant increase in both Aβ1-260 40 and Aβ1-42 in AD-derived EVs over controls (Aβ1-40: p = 0.0021 and Aβ1-42: p < 0.0001) 261 ( Figure 1E) . 262 263
Proteomic profiling of brain-derived EVs 264
We performed a label-free Nano-LC-MS/MS analysis of 38 EV samples for proteomic profiling. 265
Across both cohorts, a total of 1,088 proteins were identified with at least two unique peptides groups, with 88 proteins unique to the controls and 148 proteins unique to the AD group ( Figure 2A ). The common, AD-unique and control-unique proteins were tested for properties pertaining 270 to the 'cellular component' and 'pathway' ontologies by Gene Ontology analysis in the Database 271 for Annotation, Visualization and Integrated Discovery (DAVID). Among the 852 shared 272 proteins, 60.9% were found to be included in the extracellular exosome ontology (Figure 2B) . 273
The 148 proteins unique to the AD group were linked to mitochondria metabolism known to be 274 dysfunctional in AD brain [29] Aβ sequence was identified in APP fragments. Figure 2E shows the AD pathway from KEGG 282 pathway analysis based on 68 proteins identified in the AD group, which are designated with red 283 stars. The list of AD pathway-related proteins is provided in Supplementary Table 3 . Proteins 284 known to play an important role in AD pathogenesis, such as APP, APOE, tau and NADH-285 ubiquinone oxidoreductase (Cx I-V), were all identified in the AD group, although they were not 286 unique to this group. 287 288
Analysis of label-free quantitative proteomics comparison of AD and control brain-289
derived EVs of 949 proteins were quantified (Figure 3A, Supplementary Table 4) . The 934 quantified 292 proteins were common between AD and control groups. Between these groups, 3 proteins were 293 uniquely expressed in the controls, while 12 proteins were uniquely expressed in the AD group. 294
The principal component analysis (PCA) showed a marginal separation of the two groups 295 ( Figure 3B) . Figure 3C shows the volcano plot of the common 289 proteins which were 296 detected in more than 50% of the group (AD: n > 10 and controls: n > 9). Among these proteins, 297 15 proteins were significantly up-regulated and 3 proteins were significantly down-regulated in 298 AD compared to the control group (as determined by p <0.05 and log2 fold change threshold of 299 >1 or <-1) ( Figure 3C, and Table 2 ). The expression levels of 18 molecules identified in the AD 300 group relative to the control group are displayed in a heatmap ( Figure 3D) . We next searched for 301 brain cell-type specific molecules within the EV proteomics dataset using the mouse proteomics 302 dataset as a reference [30] . The top 100 ranked cell type-specific molecules, which have at least 303 5-fold change in concentration in the cell type of interest over the other cell types, were tested 304 with our EV proteomics dataset ( Figure 3E) . The distribution of these markers indicate that in 305 the human brain, neuron-derived EV represent 49% of EVs, while the other 50% of EVs are 306 derived from glial cell types, including microglia, astrocytes and oligodendrocytes. Moreover, 307 using label-free quantitative value, differences in the expression of cell type-specific marker 308 molecules between AD and controls were seen ( Figure 3F) . Interestingly, neuron-specific 309 molecules were enriched in the control group (Figure 3F, blue) , while glia-specific marker 310 molecules were enriched in the AD group (Figure 3F, red) . These results suggest that glia 311 enhance their generation of EVs in AD brains, which may play a role in spreading AD
Machine learning to identify distinctive AD brain-derived EV proteins 315
To discover a combination of protein molecules that can accurately distinguish AD EVs from 316 controls, the label-free quantitative proteomics dataset was analyzed using a machine learning 317 method ( Figure 4A) . For this purpose, we split the proteomics dataset into an unblinded training 318 subset (AD: n = 11; controls: n = 10) and a blinded testing subset (AD: n = 9; CTRL: n = 8). The 319 ensemble machine learning model was built using only the data from the training subset, and 320 then the accuracy of the diagnosis was determined using only the blinded testing set. We found 321 that a panel that included annexin-A5 (ANXA5), NGF-induced growth factor (VGF), neuronal 322 membrane glycoprotein M6-a (GPM6A), and alpha-centractin (ACTZ), selected by the LASSO 323 algorithm, resulted in an area under the ROC curve (AUC) of 0.95 within the training set ( Figure  324 4B and Supplementary Table 5 ). We then examined the accuracy in the independent blinded 325 test set using the 4 proteins in the dotted green box ( Figure 4B ). Using this model, we achieved 326 an 88% accuracy (AUC = 0.97) in identifying AD patients using the panel that consisted of 327 ANXA5, VGF, GPM6A, and ACTZ ( Figure 4C) . Further, we ran two control experiments that 328 randomly selected 4 proteins from a total possible 949 proteins to form the diagnosis panel 329 (repeated 20 times, AUC = 0.58, Accuracy = 55%) and shuffling the true labels of the subjects 330 within the training set (AUC = 0.47, Accuracy = 48%). The control's AUC was significantly 331 worse than using the 4-protein panel's AUC (P<0.001) ( Figure 4C) . Figure 4D shows the 332 scatter plot of selected 4 proteins from our panel individually, which were each significantly 333 differentially expressed between AD and control groups ( Supplementary Table 6 ). Next, we 334 assessed the correlation of expression of these candidate molecules to the levels of 335 phosphorylated tau (p-tau), Aβ1−40, and Aβ1−42 in EVs by Pearson's correlation analysis.
GPM6A and Aβ1-42 levels (pS396 tau: r = 0.380, p = 0.019; Aβ1-42: r = 0.387, p = 0.016), and 338 a significantly negative correlation between VGF and Aβ1-42 levels (r = -0.538, p = 0.002) 339 ( Figure 4E) . We also examined the first and second cohorts of AD and control cases to validate 340 ANXA5 expression level by ELISA. ANXA5 expression level was significantly increased in AD 341 brain-derived EVs compared to the control group (p = 0.0042, 42 AD and 36 control cases, 342 Figure 4F ). Although there was statistical difference in PMI between AD and control cases in 343 the validation cohort ( Table 1) , Pearson's correlation analysis of PMI and ANXA5 levels 344 showed no significant correlation (r = -0.165, p = 0.149). Thus, this correlation is not due to the 345 difference in PMI between the two groups. Interestingly, ANXA5 expression level shows a 346 tendency to increase along with Braak stages in an AD-dependent manner ( Figure 4F) . 347 Therefore, ANXA5 is a potential EV molecule for both distinguishing AD and control EVs and 348 as a surrogate marker for Braak stage. 349 350
Discussion 351
The biophysical properties of EVs isolated from unfixed postmortem human brain tissues, 352 quantitative analysis of tau and Aβ species, and label-free quantitative proteomic profiling by 353 Nano-LC-MS/MS analyses were performed. pS396 tau, Aβ1-40, and Aβ1-42 levels were 354 significantly increased in AD brain-derived EVs compared to controls. A total of 1,088 unique 355 proteins from brain-derived EVs, were found to be enriched as extracellular exosomes 356 molecules. We also quantified 949 proteins by label-free quantitative proteomic analysis, which 357 were enriched in neuron-specific molecules in controls and glial cell type-specific molecules in 358 the AD group. Differentially expressed EV proteins between AD and control brain samples included ANXA5, VGF, GPM6A and ACTZ as determined by machine learning approach.
Using the validation cohort with the larger sample size, the increased protein level of ANXA5 in 361 the AD group, as compared to controls was confirmed by ELISA. 362
When characterizing brain-derived EVs isolated from AD and control samples by tau-363 specific ELISA, the pS396 tau levels were found to be significantly increased in the AD group as 364 compared to the control group. Previous reports indicate pT181 tau to be an early PTM 365 associated with AD, pS199 tau modification is thought to promote tau accumulation, and pS396 366 tau modification is associated with tau seeding activity and aggregation [31, 32] . The enrichment 367 of pS396 in EVs derived from AD brain tissue may indicate their spread and aggregation of tau 368 in the AD brain. We also observed tau fragments from the mid-region (156-406), which is 369 inclusive of proline-rich domains (151-240), and microtubule binding repeat domains (244-369). 370
Tau can be cleaved by various proteases including calpain-1 and 2 (at R230), thrombin, 371 cathepsins, asparagine endopeptidase (at D255, N368), and caspase-2 (at D314) and -3 (at D421) 372 [33] [34] [35] [36] . However, many tau fragments identified in AD patients have not been well 373 characterized, and the proteases responsible for their generation have not all been identified. In 374 CSF, 25-35 kDa fragments of tau have been used as an early marker of AD; however, the 375 protease responsible for this cleavage event is unknown [37, 38] . A further detailed investigation 376 is needed to determine if tau is truncated by proteases and modified by kinases, and are enriched 377 in AD brain-derived EVs. 378
In the present study, we observed that the size of EVs derived from AD brain samples 379 was smaller than from control EVs. We propose two possible factors for this finding. First, 380 cholesterol level might be related to EV size; the CNS is known to contain 25% of the body's 381 cholesterol and accumulation of cholesterol is reported to be associated with AD [39]. High cholesterol levels increase Aβ in cellular and animal models of AD, and the chemical that 383 inhibits cholesterol synthesis reduces Aβ in this model [39] [40] [41] [42] [43] . Moreover, it has been reported 384 that small EVs contain significantly higher cholesterol than large EVs [40, 41] . Therefore, AD 385 brain cells that accumulate high cholesterol might secrete smaller EVs than controls. The second 386 possibility is that the cell of origin determines EV size. Our study found that human brain-387 derived EVs were enriched in cell-type specific molecules corresponding to 50% neuronal and 388 50% glial cell origins. Moreover, the AD brain-derived EVs were enriched with more glial-389 specific molecules compared to the control EVs. Thus, there is the possibility that the difference 390 in EV size between AD and control groups is due to an increase in smaller, glia-produced EVs 391 among AD patients. 392
Herein, we report for the first time, the quantitative proteomic analysis of a large-scale 393 brain-derived EV samples isolated from AD and control patients. A total of 59.5 % of the 394 identified 1,088 proteins were part of the extracellular exosome ontology, and similar enrichment 395 rate of EV-specific molecules was previously reported [22] . Interestingly, in AD EVs, glia-396 specific marker molecules were enriched, while neuron-specific molecules were enriched in 397 controls. Thus, there is a possibility that glia-derived EVs act as a vehicle to transfer pathogenic 398 proteins into neurons in AD brains, which are then spreading and propagating tau throughout the 399 brain. 400
In summary, we have quantified tau and Aβ levels and investigated proteomic profiles in 401 brain-derived EVs from AD, found enriched glia-specific molecules in AD brain-derived EVs, 402 and identified ANXA5, VGF, GPM6A and ACTZ as potential candidate molecules for 403 monitoring the progression of AD. Zhang et al. have recently reported that ANXA5 is associated 404 with familial late-onset AD by GWAS [44] . Further, Sohma et al. have reported a significantly studies in CSF and brain tissue have reported markedly lowered concentration of VGF in AD 407 patient groups compared to controls [46] [47] [48] [49] . GPM6A expression level has been shown to be 408 downregulated in the hippocampus of transgenic mice modeling AD [50, 51] . It has been reported 409 that GPM6A with palmitoylation is involved in the clustering of lipid rafts, which are themselves 410 enriched in sphingolipids and cholesterol [52] . Thus, GPM6A might be loaded into EVs with 411 high cholesterol levels in AD. In our study, ANXA5 was detected in brain-derived EVs from one 412 brain tissue cohort by commercial ELISA, but VGF, GPM6A, and ACTZ were undetectable. 413
Thus, assays with higher sensitivity detection are needed for the quantification of these 414 molecules. Finally, the combination of cell type-specific molecules from brain cells, including 415 ANAX5, VGF, GPM6A or ACTZ may serve as potential biomarker candidate molecules in AD 416 patient blood samples. 
